Compare NXP & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXP | EMBC |
|---|---|---|
| Founded | 1992 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 743.2M | 719.7M |
| IPO Year | N/A | N/A |
| Metric | NXP | EMBC |
|---|---|---|
| Price | $14.12 | $12.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 70.0K | ★ 697.1K |
| Earning Date | 01-01-0001 | 02-05-2026 |
| Dividend Yield | 4.04% | ★ 4.84% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | 0.54 | ★ 1.62 |
| Revenue | N/A | ★ $1,080,400,000.00 |
| Revenue This Year | N/A | $2.18 |
| Revenue Next Year | N/A | $0.09 |
| P/E Ratio | $26.81 | ★ $7.65 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.91 | $9.20 |
| 52 Week High | $14.89 | $21.23 |
| Indicator | NXP | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 52.37 |
| Support Level | $14.06 | $11.38 |
| Resistance Level | $14.19 | $12.44 |
| Average True Range (ATR) | 0.10 | 0.38 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 51.52 | 90.05 |
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.